# Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

> **NCT00785694** · PHASE4 · WITHDRAWN · sponsor: **GE Healthcare**

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** hexaminolevulinate

## Key facts

- **NCT ID:** NCT00785694
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-12
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Rejected ethics approval in UK and Holland
- **Last updated:** 2015-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00785694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00785694, "Recurrence of Bladder Cancer After Transurethral Resection With Hexvix". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00785694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*